FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2165628351> ?p ?o ?g. }

• W2165628351 endingPage "539" @default.
• W2165628351 startingPage "537" @default.
• W2165628351 abstract "The treatment course for advanced ovarian cancer is marked both by chemotherapy sensitivity at the outset and by eventual death from resistant disease in patients who relapse. Aggressive surgical debulking and platinum plus taxane therapy have improved median survival from 1 year in 1975 to approximately 5 years in 2005, but the long-term cure rate continues to languish in the 20% to 30% range. Approximately 50% of patients will enter a pathologic first complete clinical remission, yet 90% of suboptimally debulked patients and 70% of optimally debulked patients relapse in 18 to 24 months. Subsequent and repeated chemotherapy responses are often seen with ever shortening intervals until broad chemotherapy resistance develops. Opportunities to improve the outcome for patients exist by making primary therapy more effective, or by applying consolidation or maintenance approaches to patients in a complete primary or subsequent remission. Well-designed randomized studies such as the SMART study by Verheijen et al in complete clinical remission patients represent a new opportunity for progress. The SMART study, evaluating intraperitoneal therapy with yttrium-90-labeled HMFG1 murine monoclonal antibody (Y-muHMFG1), described in this issue of the Journal of Clinical Oncology, was logically based and appropriately designed. Ovarian cancer patients usually have disease localized to the peritoneal cavity at the time of progression, thus providing a rationale for intraperitoneal (IP) therapy. The small volume of disease during remission is appropriate to consider an immune mechanism. The MUC 1 antigen that Y-muHMFG1 is directed towards is well established as an attractive immunotherapy target since it is overexpressed on 90% of adenocarcinomas, including ovarian cancer. The phase II data supporting the use of Y-muHMFG1 administered intraperitoneally in patients in first remission was promising, with a Cox model estimate of 10-year survival at 70% compared to 32% of case matched controls (P .003). Patients were stratified using a second surgical assessment where disease status at second look remains a powerful predictor of ultimate progression free and overall survival. Finally, the study was adequately powered to answer the question as to whether a single intraperitoneal administration of Y-muHMFG1 for patients in remission impacted outcome. While the negative therapeutic results are disappointing and one can speculate whether changing frequency or dose could affect efficacy, the trial serves as the largest prospective randomized study of patients in a surgically defined remission population with overall survival as the outcome. The outcome of this trial reminds us all that randomized trials are the only reasonable way to move cancer therapy forward. The value of treatment in clinical complete remission was first established in acute leukemia and additional consolidation or maintenance chemotherapy dramatically improved the outcome for some of these patients. These concepts have not found a place in solid tumor therapy. Even the nomenclature is confusing. Strictly speaking, consolidation should be best applied to those strategies that are of limited duration such as high-dose chemotherapy or whole abdominal radiotherapy, and maintenance is best used to describe interventions that continue for years (or until progression). As treatment options move beyond classic cytotoxic chemotherapy to hormones, immune interventions, and targeted therapy, the consolidation strategy is regaining interest in solid tumors. A recent study, for example, showed the benefit of consolidation trastuzumab for one year in patients with breast cancer. In ovarian cancer, no randomized consolidation study has provided a statistically significant improvement in overall survival, although many attempts have been made. Negative randomized consolidation approaches include both subcutaneous and IP interferon-alfa, high-dose chemotherapy, continued intravenous carboplatin versus whole abdominal radiotherapy (WART), chemotherapy versus observation versus WART, IP radioactive phosphorus (32P), noncross resistant chemotherapy in the form of cisplatin and fluorouracil for three cyclesor topotecan for four cycles, and the monoclonal antibody orgovomab which targets CA125. With regards to IP cytotoxic chemotherapy as consolidation, no adequately powered randomized study versus observation has been completed. The only randomized study to show evidence of clinical benefit was the Southwest Oncology Group/Gynecologic Oncology Group study of ovarian cancer patients receiving three versus 12 additional cycles of intravenous paclitaxel following a complete response to platinum and paclitaxel therapy. This study showed a progression free survival advantage of 28 months versus 21 months in favor of the 12 cycle arm (hazard ratio [HR], 2.31; 99% CI, 1.08 to 4.94). Survival data is not available due to its early termination by the data safety monitoring committee. With the important exception of the paclitaxel consolidation study, the extended chemotherapy trials and radiotherapy treatments have been disappointing. A variety of clinical observations have supported the role of the immune system in determining the outcome of patients with ovarian cancer. In a study by Zhang et al with 74 patients in complete clinical remission (ie, the consolidation population), 5-year overall survival was 73.9% in those whose tumors were found to have infiltrating T lymphocytes present versus 11.9% in those that did not (P .001). The characterization of surface antigens and the JOURNAL OF CLINICAL ONCOLOGY E D I T O R I A L VOLUME 24 NUMBER 4 FEBRUARY 1 2006" @default.
• W2165628351 created "2016-06-24" @default.
• W2165628351 creator A5073323475 @default.
• W2165628351 creator A5090740287 @default.
• W2165628351 date "2006-02-01" @default.
• W2165628351 modified "2023-10-02" @default.
• W2165628351 title "Consolidation for Ovarian Cancer in Remission" @default.
• W2165628351 cites W1876291843 @default.
• W2165628351 cites W2002365489 @default.
• W2165628351 cites W2014947083 @default.
• W2165628351 cites W2024894561 @default.
• W2165628351 cites W2026017442 @default.
• W2165628351 cites W2044147848 @default.
• W2165628351 cites W2061447999 @default.
• W2165628351 cites W2079537409 @default.
• W2165628351 cites W2088298750 @default.
• W2165628351 cites W2103194390 @default.
• W2165628351 cites W2106798452 @default.
• W2165628351 cites W2115451334 @default.
• W2165628351 cites W2115951816 @default.
• W2165628351 cites W2129940924 @default.
• W2165628351 cites W2130941707 @default.
• W2165628351 cites W2136090166 @default.
• W2165628351 cites W2137074525 @default.
• W2165628351 cites W2149908785 @default.
• W2165628351 cites W2151246207 @default.
• W2165628351 cites W2159164221 @default.
• W2165628351 cites W2163184777 @default.
• W2165628351 cites W2605056405 @default.
• W2165628351 cites W4250188608 @default.
• W2165628351 cites W4239544164 @default.
• W2165628351 doi "https://doi.org/10.1200/jco.2005.04.5138" @default.
• W2165628351 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/16446325" @default.
• W2165628351 hasPublicationYear "2006" @default.
• W2165628351 type Work @default.
• W2165628351 sameAs 2165628351 @default.
• W2165628351 citedByCount "21" @default.
• W2165628351 countsByYear W21656283512012 @default.
• W2165628351 countsByYear W21656283512013 @default.
• W2165628351 countsByYear W21656283512014 @default.
• W2165628351 countsByYear W21656283512016 @default.
• W2165628351 countsByYear W21656283512019 @default.
• W2165628351 crossrefType "journal-article" @default.
• W2165628351 hasAuthorship W2165628351A5073323475 @default.
• W2165628351 hasAuthorship W2165628351A5090740287 @default.
• W2165628351 hasBestOaLocation W21656283511 @default.
• W2165628351 hasConcept C121608353 @default.
• W2165628351 hasConcept C121955636 @default.
• W2165628351 hasConcept C126322002 @default.
• W2165628351 hasConcept C143998085 @default.
• W2165628351 hasConcept C144133560 @default.
• W2165628351 hasConcept C2776014549 @default.
• W2165628351 hasConcept C2780427987 @default.
• W2165628351 hasConcept C29456083 @default.
• W2165628351 hasConcept C71924100 @default.
• W2165628351 hasConceptScore W2165628351C121608353 @default.
• W2165628351 hasConceptScore W2165628351C121955636 @default.
• W2165628351 hasConceptScore W2165628351C126322002 @default.
• W2165628351 hasConceptScore W2165628351C143998085 @default.
• W2165628351 hasConceptScore W2165628351C144133560 @default.
• W2165628351 hasConceptScore W2165628351C2776014549 @default.
• W2165628351 hasConceptScore W2165628351C2780427987 @default.
• W2165628351 hasConceptScore W2165628351C29456083 @default.
• W2165628351 hasConceptScore W2165628351C71924100 @default.
• W2165628351 hasIssue "4" @default.
• W2165628351 hasLocation W21656283511 @default.
• W2165628351 hasLocation W21656283512 @default.
• W2165628351 hasOpenAccess W2165628351 @default.
• W2165628351 hasPrimaryLocation W21656283511 @default.
• W2165628351 hasRelatedWork W1999344589 @default.
• W2165628351 hasRelatedWork W2069482181 @default.
• W2165628351 hasRelatedWork W2353260778 @default.
• W2165628351 hasRelatedWork W2365364931 @default.
• W2165628351 hasRelatedWork W2418638721 @default.
• W2165628351 hasRelatedWork W2789357466 @default.
• W2165628351 hasRelatedWork W2789448498 @default.
• W2165628351 hasRelatedWork W3003270674 @default.
• W2165628351 hasRelatedWork W3034140415 @default.
• W2165628351 hasRelatedWork W3112668456 @default.
• W2165628351 hasVolume "24" @default.
• W2165628351 isParatext "false" @default.
• W2165628351 isRetracted "false" @default.
• W2165628351 magId "2165628351" @default.
• W2165628351 workType "article" @default.